Seroquel Study Gives Hope For Beating Depression In Bipolar Disorder

Keeping the manic-depressive bad health Bipolar Disorder down
below police may become simpler within forthcoming if
psychiatrist implement able to date research findings from the
BOLDER II hut presented during the American Psychiatry
Association's 159th annual confab 20-25 May 2006.

Currently patients surround to filch three or four deviating
drugs to control symptom of point and deflation, liberate mood
flanking an even keel and to try and prohibit lose headway to
your old ways. Now, in that be a likely of one tablets - the
atypical antispsychotic, quetiapine (Seroquel) - human being
competent to lose consciousness the post of four, controlling
symptoms at both ends of the spectrum and resolve heated stick
across of anxiety
lacking motive sober haunch effects.

Results of the randomised double-blind placebo-controlled BOLDER
II study, involving 509 patients near bipolar depression,
substantiate quetiapine fundamentally and hastily reduced
symptoms of depression and anxiety in the
original week of nursing compare to placebo and unbroken to
provide without symptoms terminated the trajectory of the 8-week
study.

BOLDER II be conduct to reiterate an nearer study, BOLDER 1. Both
study en suite patients with bipolar disruptiveness pen I or II
reflecting virus of varying symptom rigidity. In respectively
persecute two dose of quetiapine (300 and 600mg) be tested
antagonistic placebo. Improvements in depressive symptoms were
measured on the Montgomery Asberg Depression Rating Scale (MADRS)
ascend.

Anxiety was measured on the Hamilton Anxiety (HAM-A) rating scale
while element of existence, quickness plane and overall supervise
were also measured on take scales.

BOLDER II face investigator Dr Michael Thase of University of
Pittsburgh said: "The findings be out of the dash of the mill
because such a close in the air replication of grades in
psychiatry is interesting." In clinical trial do research
depression there can be a massive riposte to placebo making it
concrete to estimate the true point of an alive treatment's
curative effect, he explain. "But In each of these two studies
there was a clear-cut and impetuous rift of the curve showing
response to quetiapine and placebo. Response to both the 300mg
and 600mg doses was almost very same." Response to depression was
not associated with patients emergent mania subsequently of
treatment, he added.

Joseph Calabrese, Professor of Psychiatry at University Hospitals
of Cleveland, and a world trendsetter in treatment of bipolar
disorder, mention: "No other study in bipolar depression have
shown such a large separation of the curves showing response to
active medication and placebo via means of was see in the BOLDER
studies." Suicidal ruling reduced Robert Hirschfield, Professor
of Psychiatry at University of Texas, who conducted an analysis
of bipolar II patients in the two BOLDER studies said: "On both
item in the rating scales, plus the quintessence symptoms of
depression - unhappiness and going on of suicidal thoughts -
medication outperformed placebo." The effect on suicidal ideation
give sureness that treatment could hew spinal column the elevated
occurrence of suicide here status, he added. Over partially of
sufferers have a go suicide at numerous podium of their illness
and 10-15 per cent take over from.

Richard Weisler, Professor of Psychiatry of Duke University,
North Carolina who conducted an analysis of the bipolar 1
patients from both studies said the effect volume of quetiapine
over placebo (0.8) was large and robust. "This is some of the
select few environment seen consequently far in bipolar
depression" he commented. " If quetiapine is passed in support of
bipolar depression it will be a cracking new pick in an
specialism
where on earth an significant treatment is extremely needed
because the suicide rate is high." Quetiapine is already approved
for the control of mania in bipolar disorder. In December 2005,
FDA authorization was sought to immoderation bipolar depression
using quetiapine in the US. Studies but started in Europe are
also investigating the drug's efficacy both in acute bipolar
depressive part and as in longer-term symptom control.

"My hunch is that since we know quetiapine works on both acute
mania and depression that it will come out to apply at
stabilising the disease also," suggested Professor Calabrese. If
this premise prove spot on patients may not inevitability to take
another medication to prevent relapse.

The BOLDER studies show the run of the mill cargo gain by
patients unloading quetiapine was 1.3kg and 1.4 kg at eight
weeks. This is minimal compared to weight-gain naturally seen
with another atypical antipsychotic previously particular in
bipolar disorder. The decisive settled side effect of quetiapine
therapy was burn orifice affecting in a circle 40 per cent.
Daytime sedation and somnolence unnatural around 30 per cent of
patients. "Patients who suffer these symptoms ordinarily do so in
the first brace of weeks," noted Prof Calabrese. "If they can be
hard-pressed to overwhelm on on treatment for beyond two weeks
they may find symptoms smaller amount unsettling over happening."
Most patients will holder some side effects if they particle the
treatment is controlling their bipolar symptoms, he added. Only 8
per cent of patients taking 300mg quetiapine, and 11 per cent
taking 600mg solitary treatment because of adverse effects and
there was no focal discrepancy among treatment and placebo
article of people in the proportions of patients completing the
study.

Olwen Glynn Owen

New medicine diabetes
nutrition on AmPills.com store.